Unapproved New Drugs/Misbranded: FDA Warning Letter to Pure Arylcyclohexylamine Store / www.arylcyclohexylamine.com, 2026-06-23
Letter issued · posted to fda.gov .
Subject as published: Unapproved New Drugs/Misbranded
TL;DR
At a glance: FDA Center for Drug Evaluation and Research issued a warning letter (MARCS-CMS 725151) to Pure Arylcyclohexylamine Store (www.arylcyclohexylamine.com) on June 23, 2026, for introducing unapproved and misbranded ketamine products into interstate commerce, including "KETAMINE 100ML (50MG/ML)" and "KETAMINE TROCHES," in violation of sections 301(a), 301(d), 502(f)(1), 503(b)(1), and 505(a) of the Federal Food, Drug, and Cosmetic Act. The letter states these products lack FDA approval and may pose serious health risks including contamination, varying active ingredient amounts, and injection-related dangers such as sepsis, and requests the entity cease offering these drugs to U.S. consumers.
Argus analysis
# FDA Warning Letter Analysis: Pure Arylcyclohexylamine Store
**Company and Violations**
The FDA's Center for Drug Evaluation and Research (CDER) issued a warning letter on June 23, 2026, to Pure Arylcyclohexylamine Store, an online retailer operating at www.arylcyclohexylamine.com. The agency documented significant violations during a website review conducted on February 27, 2026. The FDA found that the company was introducing unapproved and misbranded ketamine products into interstate commerce, including formulations marketed as "KETAMINE 100ML (50MG/ML)" and "KETAMINE TROCHES." The letter emphasizes particular concern because some FDA-approved ketamine versions are restricted injectable products or subject to Risk Evaluation and Mitigation Strategies (REMS), requiring medical supervision and controlled distribution channels that these unapproved versions bypass entirely.
**Regulatory Citations and Implications**
The violations cite sections 301(a), 301(d), 502(f)(1), 503(b)(1), and 505(a) of the Federal Food, Drug, and Cosmetic Act. Section 505(a) requires FDA approval before introducing new drugs into commerce; the company lacked such approval. Section 502(f)(1) mandates adequate directions for use, which prescription drugs cannot satisfy for layperson self-administration. Section 503(b)(1) designates certain substances as prescription-only due to toxicity or complexity requiring professional supervision. These citations reflect foundational drug-approval requirements meant to ensure safety and efficacy documentation before market distribution.
**Timeline and Industry Monitoring**
The company received 180 days from the warning letter date to respond with corrective actions. Compliance officers in pharmaceutical e-commerce should monitor for follow-up enforcement actions, including potential seizures or injunctions if the company fails to cease sales. Peers should also note FDA's stated concern about ketamine product proliferation online and heightened scrutiny of any unapproved dissociative or controlled-substance sales through internet channels.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Pure Arylcyclohexylamine Store / www.arylcyclohexylamine.com MARCS-CMS 725151 — June 23, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Recipient: Pure Arylcyclohexylamine Store / www.arylcyclohexylamine.com United States admin@arylcyclohexylamine.com arylcyclohexylaminesales@gmail.com Issuing Office: Center for Drug Evaluation and Research (CDER) United States June 23, 2026 WARNING LETTER Reference Number: MARCS-CMS 725151 To PURE ARYLCYCLOHEXYLAMINE STORE: This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website www.arylcyclohexylamine.com. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that you comply with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. As discussed below, FDA has observed that www.arylcyclohexylamine.com introduces into interstate commerce unapproved and misbranded ketamine drug products, including certain drugs for which the FDA-approved version is an injectable or subject to a Risk Evaluation and Mitigation Strategy (REMS). 1 FDA has identified significant risks associated with unapproved ketamine products, especially in the absence of appropriate medical supervision. Given the increased interest in the use of ketamine products, the easy availability of unapproved and misbranded ketamine products via the internet puts U.S. consumers at risk for serious adverse events. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body's natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis. There are also inherent risks to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. Accordingly, FDA requests that www.arylcyclohexylamine.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm. FDA Review Violations were identified and documented during a review of your website www.arylcyclohexylamine.com, FDA E…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What is the regulatory background for a Unapproved drug warning letter?
- Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Pure Arylcyclohexylamine Store / www.arylcyclohexylamine.com had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Pure Arylcyclohexylamine Store / www.arylcyclohexylamine.com as of 2026-07-07. Argus ingests new FDA enforcement records daily.
- What FDA violations was Pure Arylcyclohexylamine Store / www.arylcyclohexylamine.com cited for?
- The FDA Warning Letter to Pure Arylcyclohexylamine Store / www.arylcyclohexylamine.com (issuing office: Center for Drug Evaluation and Research (CDER)) cites: Unapproved New Drugs/Misbranded. Classification: Unapproved drug.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Unapproved New Drugs/Misbranded: FDA Warning Letter to Pure Arylcyclohexylamine Store / www.arylcyclohexylamine.com, 2026-06-23. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-pure-arylcyclohexylamine-store-www-arylcyclohexylamine-com-2026-06-23-unapproved
"Unapproved New Drugs/Misbranded: FDA Warning Letter to Pure Arylcyclohexylamine Store / www.arylcyclohexylamine.com, 2026-06-23." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-pure-arylcyclohexylamine-store-www-arylcyclohexylamine-com-2026-06-23-unapproved.
Argus HQ Research. "Unapproved New Drugs/Misbranded: FDA Warning Letter to Pure Arylcyclohexylamine Store / www.arylcyclohexylamine.com, 2026-06-23." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-pure-arylcyclohexylamine-store-www-arylcyclohexylamine-com-2026-06-23-unapproved.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_pure_arylcyclohexylamine_store_www_arylcyclohexylamine_com_2026_06_23_unapproved_2026,
title = {Unapproved New Drugs/Misbranded: FDA Warning Letter to Pure Arylcyclohexylamine Store / www.arylcyclohexylamine.com, 2026-06-23},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-pure-arylcyclohexylamine-store-www-arylcyclohexylamine-com-2026-06-23-unapproved},
note = {Accessed: July 13, 2026}
}